X0306 4 2014-12-30 0 0000816284 CELGENE CORP /DE/ CELG 0001260573 KARSEN PERRY A C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 0 1 0 0 see remarks Common Stock 2014-12-30 4 M 0 23334 29.75 A 74744 D Common Stock 2014-12-30 4 S 0 19273 113.37 D 55471 D Common Stock 2000 I IRA Account Common Stock 1461 I 401(k) Plan Stock Option (right to buy) 29.75 2014-12-30 4 M 0 23334 0.00 D 2020-12-27 Common Stock 23334 0 D The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan in multiple transactions at prices ranging from $112.78 to $114.25, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. The option was fully exercisable. The option was issued pursuant to the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 17, 2013). Chief Executive Officer, Celgene Cellular Therapeutics /s/Robert J Hugin_________________ Robert J Hugin, Attorney-in-Fact 2015-01-02